Cassani Chiara, Dominoni Mattia, Pasquali Marianna Francesca, Gardella Barbara, Spinillo Arsenio
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Department Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Front Med (Lausanne). 2024 Jul 15;11:1403548. doi: 10.3389/fmed.2024.1403548. eCollection 2024.
This study aimed to evaluate the prevalence of multiple high-risk (HR) human papillomavirus (HPV) infections in women with human immunodeficiency virus (HIV) compared to negative controls. This study also aimed to assess the impact of multiple HR-HPVs on the risk of high-grade squamous cervical lesions (HSILs) among women with HIV.
We performed a systematic search of PubMed/Medline, Scopus, Cochrane databases, and ClinicalTrials.gov from 1 January 2004 to 30 June 2023, including screenings and clinical studies evaluating the rates and role of multiple HPV infections in squamous intraepithelial lesions (SILs). Three reviewers independently screened the abstracts of the selected studies and extracted data from full-text articles. The data were subsequently tabulated and compared for consistency. The bias associated with each included study was evaluated according to the OSQE method.
Forty-seven studies meet definitive inclusion criteria. The quality of the observations was considered low in 26 of the included studies and moderate in 21 of the included studies. In comparative screening studies, the pooled prevalence of multiple HR-HPV was 39.1% (95% CI = 33.7-44.7) among women with ( = 1734) and 21.6% (95% CI = 17.3-26.1) in those without HIV infection ( = 912) (OR = 2.33, 95% CI = 1.83-2.97, = 2.8%). The pooled ORs of HR-HPV multiple infections were similar in African (OR = 2.72, 95% CI = 1.89-3.9) and non-African countries (OR = 2.1, 95% CI = 1.46-3, for difference = 0.96). Among women with HIV, the risk of HSIL diagnosed either by cytology or histology was higher among those with overall (OR = 2.62, 95% CI = 1.62-4.23) and HR multiple infections than those with single HPV infection (OR = 1.93, 95% CI = 1.51-2.46). Among women with HIV, the excess rates of multiple HPV infections and the excess risk of associated HSIL were consistent across studies including both HIV-naïve subjects and those on antiretroviral therapy, as well as in studies with different rates of immunocompromised women. When study quality (low vs. moderate) was used as a moderator, the results were unchanged.
Multiple HR-HPV infections are common among women living with HIV and are associated with an increased prevalence of HSIL. These associations were also confirmed in studies with high rates of antiretroviral therapy and low rates of immunocompromise.: PROSPERO [registration number: CRD42023433022].
本研究旨在评估与阴性对照相比,感染人类免疫缺陷病毒(HIV)的女性中多重高危(HR)人乳头瘤病毒(HPV)感染的患病率。本研究还旨在评估多重HR-HPV对HIV感染女性发生高级别鳞状上皮内病变(HSIL)风险的影响。
我们对2004年1月1日至2023年6月30日期间的PubMed/Medline、Scopus、Cochrane数据库和ClinicalTrials.gov进行了系统检索,包括评估多重HPV感染在鳞状上皮内病变(SIL)中的发生率和作用的筛查及临床研究。三位评审员独立筛选所选研究的摘要,并从全文文章中提取数据。随后将数据制成表格并进行一致性比较。根据OSQE方法评估每项纳入研究的偏倚。
47项研究符合最终纳入标准。纳入的26项研究观察质量被认为较低,21项研究观察质量为中等。在比较性筛查研究中,HIV感染女性(n = 1734)中多重HR-HPV的合并患病率为39.1%(95%CI = 33.7 - 44.7),未感染HIV的女性(n = 912)中为21.6%(95%CI = 17.3 - 26.1)(OR = 2.33,95%CI = 1.83 - 2.97,P = 2.8%)。HR-HPV多重感染的合并OR值在非洲国家(OR = 2.72,95%CI = 1.89 - 3.9)和非非洲国家(OR = 2.1,95%CI = 1.46 - 3,差异P = 0.96)相似。在HIV感染女性中,通过细胞学或组织学诊断为HSIL的风险,在总体多重感染(OR = 2.62,95%CI = 1.62 - 4.23)和HR多重感染的女性中高于单一HPV感染的女性(OR = 1.93,95%CI = 1.51 - 2.46)。在HIV感染女性中,多项研究中多重HPV感染的超额率及相关HSIL的超额风险在初治HIV受试者和接受抗逆转录病毒治疗的受试者中一致,在免疫功能低下女性比例不同的研究中也一致。当以研究质量(低质量与中等质量)作为调节因素时,结果不变。
多重HR-HPV感染在HIV感染女性中很常见,且与HSIL患病率增加相关。这些关联在抗逆转录病毒治疗率高且免疫功能低下率低的研究中也得到了证实。:国际前瞻性系统评价注册库[注册号:CRD42023433022]